Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Renal Cell 2Neoplasms 1Kidney Neoplasms 1Kidney Diseases 1

Interventions

pembrolizumab 30Cisplatin 20Carboplatin 20Paclitaxel 18Dexamethasone 15Pemetrexed 13Nivolumab 13Ipilimumab 12Fluorouracil 11Cyclophosphamide 11Gemcitabine 10Trastuzumab 9Docetaxel 9Cytarabine 9daratumumab 8atezolizumab 8Rituximab 8Capecitabine 8Lenalidomide 7Doxorubicin 7zanubrutinib 6Prednisone 6Daunorubicin 6Bortezomib 6venetoclax 5trametinib 5nilotinib 5ibrutinib 5fludarabine 5dabrafenib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Has announcements × Axitinib × Clear all
NCT02853331 2026-02-02

KEYNOTE-426

Merck Sharp & Dohme LLC

Phase 3 Completed
861 enrolled 24 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell

NCT02684006 2025-07-30

JAVELIN Renal 101

Pfizer

Phase 3 Completed
886 enrolled 37 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡